XBiotech competitors

Garo H. Armen is a Turkish-born American businessman of Armenian descent. He is the co-founder of Agenus, Inc. and the founder of the Children of Armenia Fund (COAF), a non-profit organization which focuses on reducing poverty, through “education, healthcare, community and economic development”.

Hamza Suri is a President & CEO at AnaptysBio Inc.

Dr. Travis Mickle founded KemPharm, Inc. in late 2006. Prior to KemPharm, from January 2003 to October 2005, Dr. Mickle was Director of Drug Discovery and Chemical Development at New River Pharmaceuticals where he also served in a variety of other senior research roles since joining the firm in 2001. During his tenure at New River, Dr. Mickle was responsible for creating a strong preclinical and clinical pipeline of drugs in the areas of ADHD, pain and thyroid dysfunction. His contributions included, as principal inventor, the discovery and development of lisdexamfetamine dimesylate, the highly successful therapy for the treatment of ADHD known as Vyvanse®. In addition, Dr. Mickle was an active participant in FDA and DEA meetings representing the company’s discovery/chemistry group and was also called in as a critical scientific resource during New River’s financings and strategic partnering discussions. Before his departure, Dr. Mickle played an integral part in New River’s development into a successful publicly-traded company which was subsequently acquired for $2.6 billion by its marketing partner, Shire PLC. Dr. Mickle is also the author of over 150 U.S. and international patents and patent applications, as well as several research papers. Dr. Mickle holds a Ph.D. in Bio-Organic Chemistry from the University of Iowa.

Ron Squarer serves as Chairman and Executive Advisor at ADC Therapeutics SA (NYSE: ADCT) and directly supported the May 2020 company IPO. Mr. Squarer served as Chief Executive Officer and a member of the Array Biopharma Board of Directors from April 2012 through August 2019 when Pfizer Inc. acquired the company for $11.8 billion following the successful launch of the cancer treatments Braftovi® and Mektovi®. During his tenure, the company’s valuation grew ~40-fold through execution across research, development, and commercialization focused in the Oncology area. Array Biopharma’s research team is recognized for having invented Vitrakvi®/larotrectinib/TRK, Koselugo®/selumetinib/MEK, Tukysa®/tucatinib/HER2, ipatasertib/AKT, selpercatinib/RET, and MRTX849/KRAS-G12C among other molecules. Mr. Squarer has extensive commercial, development, research prioritization, and executive leadership expertise from a career spanning more than two decades in the biopharmaceutical industry. Before joining Array, Mr. Squarer held positions of increasing responsibility with Hospira, Inc., a global pharmaceutical and medical device company. In his last role there, as Senior Vice President and Chief Commercial Officer, he was responsible for delivering $4 billion in annual revenue. Mr. Squarer joined Hospira from Mayne Pharma, where he served as Senior Vice President, Global Corporate and Business Development when Mayne was sold to Hospira in 2007 for over $2 billion. Before Mayne Pharma, Mr. Squarer held leadership roles at both Pfizer, Inc. (including in Oncology), and SmithKline Beecham Pharmaceuticals (now GlaxoSmithKline) in the U.S. and Europe and currently serves as a member of the Board of Directors of Deciphera Inc. (NASDAQ: DCPH) and Travere Therapeutics Inc. (NASDAQ: TVTX) Mr. Squarer earned an MBA from the Kellogg School of Management, Northwestern University, and a bachelor’s degree in biochemistry from the University of California, Berkeley.

Serial Entrepreneur experienced in high tech start ups. Twenty years of extensive knowledge in managing complex technologies and technology product development. A proven track record of conceiving and growing companies from concept to successful market entry, developing new product concepts, sourcing and managing co-development activities both in US and in China. Demonstrated success in building and leading multi-functional teams, strategic planning, and decision making. Also an inventor with 25 issued US patents and experience in developing and managing Intellectual Property. Specialties: Conceiving and developing high tech business from concept to commercial success. Team building in high tech start up companies. Integrated product development and commercialization.

Mr. Christopher P. Kiritsy co-founded Arisaph Pharmaceuticals, Inc. in 1999 and has been its Chief Executive Officer & President since June 2005. Mr. Kiritsy served as Consultant of Kos Pharmaceuticals Inc. since May 23, 2005. He served as an Executive Vice President, Corporate Development and Chief Financial Officer of Kos Pharmaceuticals Inc., until May 20, 2005. He served as Senior Vice President of Kos Pharmaceuticals Inc. He played a key operating role in commercializing Kos' two internally developed cholesterol therapies (Niaspan® and Advicor®). In 1999, while serving as Director of Business Planning at Kos Pharmaceuticals, a non-executive officer position, and before Kos Pharmaceuticals conducted business with Triad, Mr. Kiritsy acted as advisor to Mr. Jaharis in connection with his initial investment in Triad. He is a seasoned entrepreneur and possesses 17 years of unique business and technical experience, previously holding senior management positions in R&D and general management, including business development and finance. He has been Director of Avaxia Biologics, Inc since April 2012. Mr. Kiritsy serves as a Member of the Advisory Board of Vatera Healthcare Partners (also known as Vatera Capital LLC). He has been a Director of Arisaph Pharmaceuticals, Inc. since 1999. He has been a member of the Board of Directors of Triad since 1999. He served as Associate Director of Product Development at the Institute of Molecular Biology, where he co-authored several publications in scientific journals. Mr. Kiritsy received an A.B. from Bowdoin College in Biology and an M.B.A. from Boston University.